Endocyte's ovarian cancer drug fails trial, shares sink Reuters India Apart from vintafolide, which is also being tested in lung and breast cancers, Endocyte is developing two more cancer drugs based on the same technology. Endocyte and Merck signed a $1 billion partnership for the drug, also called Vynfinit, in April 2012. |
